FLUOXETINE ATTENUATES MAST CELL FUNCTION BY  TARGETING PURINERGIC SIGNALING by Haque, Tamara T.
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2019 
FLUOXETINE ATTENUATES MAST CELL FUNCTION BY 
TARGETING PURINERGIC SIGNALING 
Tamara T. Haque 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Immunology and Infectious Disease Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/5996 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
i 
 
 
Fluoxetine Attenuates Mast Cell Function by Targeting Purinergic Signaling 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
by 
Tamara T. Haque 
BS, Virginia Commonwealth University 
Director: John J. Ryan, Professor Department of Biology 
 
Virginia Commonwealth University 
Richmond, Virginia 
August, 2019 
 
 
 
 
 
 
 
 
 
ii 
 
 
 
 
 
 
 
 
©Tamara Haque                                        2019 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
Table of Contents 
Acknowledgements ...................................................................................................................................... vi 
Abstract ....................................................................................................................................................... vii 
Chapter 1: Introduction ................................................................................................................................ 1 
Brief Introduction to The Immune System ............................................................................................... 1 
Mast cells and their role in allergy and asthma ........................................................................................ 2 
Purinergic signaling ................................................................................................................................... 7 
Selective serotonin reuptake inhibitors .................................................................................................... 8 
Figure 1 Mast cells contribute to innate as well as adaptive immune responses .............................. 10 
Figure 2: IgE and Its High Affinity Receptor ........................................................................................ 11 
Figure 3: IgE Signaling Cascade ........................................................................................................... 12 
Figure 4: SSRI Chemical Structures ..................................................................................................... 13 
Chapter 2: Methods .................................................................................................................................... 14 
Mouse mast cell culture: ..................................................................................................................... 14 
Mouse basophil culture: ..................................................................................................................... 14 
Mouse eosinophil culture: .................................................................................................................. 14 
Human skin mast cells:........................................................................................................................ 15 
Animals:............................................................................................................................................... 15 
Supernatant Cytokine Measurement: ................................................................................................ 15 
Degranulation: .................................................................................................................................... 16 
RT-qPCR: .............................................................................................................................................. 16 
Drugs and Inhibitors: ........................................................................................................................... 17 
Intracellular Cytokine Staining: ........................................................................................................... 17 
Mass Spectrometry for Lipid Detection: ............................................................................................. 17 
Passive Systemic Anaphylaxis: ............................................................................................................ 19 
Flow Cytometry: .................................................................................................................................. 20 
Intracellular Calcium Flux Assay: ......................................................................................................... 20 
NFκB reporter activity: ........................................................................................................................ 21 
siRNA Knock Down Experiments: ........................................................................................................ 21 
Western Blot: ...................................................................................................................................... 22 
HDM Sensitization, Airway Hypersensitivity and Lung Inflammation Model: .................................... 22 
iv 
 
Chapter 3: Results ....................................................................................................................................... 24 
SSRIs Suppress IgE-mediated cytokine production in BMMCs and PMCs .............................................. 24 
Extracellular serotonin or the serotonin transporter is not involved in fluoxetine’s mechanism.......... 27 
P2X3 is expressed on BMMCs and is necessary for fluoxetine induced suppression ............................. 27 
Fluoxetine suppresses ATP-induced mast cell activation ....................................................................... 28 
Fluoxetine suppresses mast cell-dependent anaphylaxis in vivo ........................................................... 29 
Fluoxetine suppresses HDM-induced lung AHR and inflammation ........................................................ 30 
Fluoxetine and other innate immune cells ............................................................................................. 31 
Fluoxetine suppresses human mast cells, human mast cells express P2X3 ........................................... 32 
Figures ......................................................................................................................................................... 33 
Figure 4 Panel of SSRIs suppress C57BL/6 BMMCs: ............................................................................ 33 
Figure 5: SSRIs Tested on Balb/c and 129/sv BMMCs. ........................................................................ 34 
Figure 6 Fluoxetine Kinetics and Viability ........................................................................................... 35 
Figure 7 Intracellular and mRNA cytokine levels ................................................................................ 36 
Figure 8 Fluoxetine Suppresses IgE-mediated Degranulation and Calcium Influx: ............................ 37 
Figure 9 Fluoxetine Suppresses IgE-induced Inflammatory Lipid Secretion: ...................................... 38 
Figure 9C Fluoxetine Suppresses IgE-induced Inflammatory Lipid Secretion: .................................... 39 
Figure 10 Peritoneal Derived Mast cells: ............................................................................................ 40 
Figure 11 Fluoxetine Suppresses IgE induced signaling: ..................................................................... 41 
Figure 12 Serotonin pretreatment of BMMCs: ................................................................................... 42 
Figure 13 Fluoxetine Dose Response on SERT Deficient BMMCs ....................................................... 43 
Figure 14 Fluoxetine dose response on siRNA induced SERT KD BMMCs .......................................... 44 
Figure 15 P2X Inhibitor Effects on cytokine production in BMMCs. ................................................... 45 
Figure 16 Fluoxetine dose response on P2X7 or P2X3 knock down BMMCs. ..................................... 46 
Figure 16B P2X3 Expression on BMMCs after fluoxetine treatment. ................................................. 47 
Figure 17 IgE induced ATP release and ATPase effects on IgE induced cytokine production. ........... 48 
Figure 18 Fluoxetine Suppresses ATP mediated BMMC Activation. ................................................... 49 
Figure 19 P2X3 Inhibition Suppresses phosphorylation of Syk. .......................................................... 50 
Figure 20 Fluoxetine Suppress Mast cell function in vivo. .................................................................. 51 
Figure 20D Histamine Induced Anaphylaxis........................................................................................ 52 
Figure 21A Mouse HDM-AHR model .................................................................................................. 53 
Figure 21B HDM induced lung resistance. .......................................................................................... 54 
Figure 21C Lung Mast Cells. ................................................................................................................ 55 
v 
 
Figure 21D Lung Eosinophils. .............................................................................................................. 56 
Figure 21E Lung T cells. ....................................................................................................................... 57 
Figure 21F BALF Eosinophils................................................................................................................ 58 
Figure 21G BALF Neutrophils. ............................................................................................................. 59 
Figure 21H BALF Lymphocytes. ........................................................................................................... 60 
Figure 21I BALF Cytokines. .................................................................................................................. 61 
Figure 21J Plasma Ig Levels ................................................................................................................. 62 
Figure 22 Basophils. ............................................................................................................................ 63 
Figure 22D Basophils. .......................................................................................................................... 64 
Figure 23 Eosinophils. ......................................................................................................................... 65 
Figure 24 Human Mast cells ................................................................................................................ 66 
Figure 25 P2X3 Expression in male vs. female BMMCs. ..................................................................... 67 
Chapter 4: Discussion .................................................................................................................................. 68 
Figure 26 Summary figure ................................................................................................................... 72 
References .................................................................................................................................................. 73 
 
 
 
 
 
 
 
                                                                                                                                
 
 
 
vi 
 
 
Acknowledgements 
First I would like to thank Dr. Ryan for his mentorship and guidance for the past 6 years. His 
continued enthusiasm and encouragement have made it possible to complete my graduate 
studies with confidence. I would also like to thank all the members of the Ryan lab, past and 
present. I am eternally grateful to the past members for the time they spent training and 
teaching me during my earlier years in the lab, and the current members for their willingness to 
help when finishing this project seemed unendurable. I would also like to thank the many 
collaborators who have contributed to data collection and analysis for this project. I would like 
to thank my committee members for their suggestions and insight. Lastly, I would like to thank 
my friends and family for being understanding when I lacked work-life balance and for helping 
me find that balance.  
 
 
 
 
 
 
 
 
vii 
 
Abstract 
Mast cells are tissue resident, innate immune cells that provide protection against parasitic and 
bacterial infections and venom poisoning. Mast cells also play a pathogenic role in atopy and 
allergic diseases. Atopy and allergic diseases are increasing in the developed world and are 
predicted to continue to increase at an alarming rate. Current treatment options include 
corticosteroids, anti-histamines, anti-IgE and avoidance of allergen. These interventions have 
limitations: some patients are steroid resistant; anti-histamines have low efficacy since they 
need to be administered early during allergen exposure; and anti-IgE is costly.  Thus there is a 
clinical need for new treatment options. An efficient approach is to re-purpose FDA-approved 
drugs. Selective serotonin reuptake inhibitors (SSRIs) are a class of anti-depressants used to 
treat depression and other psychiatric disorders. SSRIs have been shown to possess anti-
inflammatory properties, but the mechanism of action is unclear. The possibility to treat allergic 
diseases with SSRIs has not been studied. Using primary mouse bone marrow derived, ex vivo 
cultured mouse peritoneal, and primary skin derived human mast cells, we show that the SSRI 
fluoxetine suppresses IgE-mediated degranulation, cytokine production, and inflammatory lipid 
secretion. Several other SSRIs showed similar effects on mouse mast cells. Cytokine suppression 
occurs at a transcriptional level, as evidenced by decreased signaling downstream of the IgE 
receptor and reduced cytokine mRNA induction. We found that fluoxetine-mediated 
suppression requires the purinergic receptor, P2X3. Furthermore, we show that IgE stimulation 
elicits rapid ATP release from mast cells, and that ATP and purinergic signaling is a positive 
feedback regulator of mast cell activation. Fluoxetine can also suppress ATP-mediated cytokine 
production, degranulation, and lipid production most likely via NFb suppression and 
viii 
 
diminished purinergic receptor expression. Importantly, fluoxetine effects are consistent in an 
in vivo passive systemic anaphylaxis (PSA) model and in a house dust mite (HDM) airway 
hyperresponsiveness and lung inflammation model of asthma. In the PSA model, fluoxetine 
reduced hypothermia and cytokine production. In the asthma model, the drug suppressed 
bronchoresponsiveness as well as pulmonary mast cell hyperplasia and eosinophilia, and the 
recruitment of Th2 cells, neutrophils, eosinophils, and lymphocytes to the bronchoalveolar 
space, as well as cytokine levels in the bronchoalveolar fluid in sensitized mice. Overall, we 
show that fluoxetine broadly suppresses mast cell activation in vitro and in vivo, most likely by 
impeding an ATP-P2X3 positive feedback loop.  
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Chapter 1: Introduction 
 
Brief Introduction to The Immune System 
Immunity is a complex system that protects the host against pathogenic organisms, 
toxins, and cancerous growth. Although it is necessarily complex, the classical categorization of 
the immune system involves two arms, the adaptive and innate. The adaptive immune system 
largely consists of antigen-activated T helper cells priming B cells and cytotoxic T cells to 
differentiate into the mature, activated states. B cells differentiate into immunoglobulin (Ig) 
producing plasma cells. Immunoglobulin facilitates pathogen recognition and destruction. 
Because the cells involved generate long-lived, antigen-specific memory cells, the adaptive 
response provides protection from re-infection. But because this response can require a week 
to be fully functional during a first time exposure, a less specific and more rapid system is also 
needed to protect the host.  
The innate immune system reaction time is quick and non-specific. Neutrophil function 
is a vital example of innate immunity. Neutrophils can respond to common bacterial products, 
such as LPS, and release reactive oxygen species (ROS) and toxins to broadly kill other cells in 
the micro-environment1. Mast cells are an innate immune cell that serves as a bridge to 
adaptive immunity (fig.1)2.  In addition to responding to common bacterial products, mast cells 
bind IgE and IgG immunoglobulins through expression of FcεRI and Fcγ receptors, which 
stimulate mast cell function. They also express TLRs, ST2, many cytokine receptors, and 
purinergic receptors that respond to innate signals independent of immunoglobulins3–5.  
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IgE-mediated mast cell activation is the most studied area of mast cell biology and likely 
the most clinically relevant. Parasitic infection induces a strong Th2 and ILC2 cell response, 
leading to IL-4 and IL-13 secretion that instructs B cells to secrete IgE6. IgE and mast cells play a 
key role parasitic clearance. Because parasitic infection is a strong evolutionary pressure and is 
still very common in undeveloped countries, the Th2-IgE-mast cell response is well ingrained in 
humans. However, IgE is also made against non-pathogenic environmental antigens termed 
allergens, which are the driving force behind the widespread occurrence of allergic disease in 
the developed world. In first world nations, mast cells are mostly studied in the context of their 
pathologic involvement in allergic diseases. In the US alone, 19 million adults and 6.2 million 
children have asthma and 25.5 million people were diagnosed with hay fever in 2017 7 8 9.  
 
Mast cells and their role in allergy and asthma  
Mast cells were first described nearly 140 years ago by Paul Ehrlich10. He named these 
aniline dye-positive cells “mastzellen” with the belief that these cells served a phagocytic 
function due to their high granularity. Mastzellen means cells that eat or to ingest in German, 
Paul Ehrlich’s native language. Many years later, it was discovered that the granular contents 
reacting to the aniline dye were heparin and histamine and that both are released during 
anaphylactic shock. Early studies were conducted with compound 48/80 since IgE and FcεRI 
were not yet discovered. Mast cell involvement in allergic disease is now well documented as 
typically occurring through IgE-dependent mechanisms.  
The identification of IgE and its binding to the high affinity receptor on the mast cell 
surface in the late 1960’s-early 1970’s by the Ishizakas and others laid the ground work for 
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studying IgE-mediated mast cell and basophil activation and allergies11,12. Following this 
discovery, other pro-inflammatory mediators released by IgE-activated mast cells were found. 
Stimulated mast cells were shown to produce the cytokines IL-3, IL-4, IL-5, IL-6, GM-CSF, and 
TNF, a list that continues to grow13 14 15 . Products of arachidonic acid metabolism, leukotrienes 
and PGD2, were shown by Frank Austen and others to be released from mast cells during 
anaphylactic shock, through IgE-dependent mechanisms16 . Mast cells were also shown to 
produce specific proteases (MCP) called tryptase and chymases 17 18. These proteases play a key 
role in innate protection against snake venom, parasitic and even bacterial infections19,20,5. The 
production of eicosanoids, proteases and other mediators vary based on the tissue of origin, 
leading to the characterization of connective tissue and mucosal mast cells in mice and MCT 
(tryptase+) and MCTC (tryptase/chymase+) mast cells in humans21. Thus mast cells are 
heterogenous and adaptable for optimal function based on their environment.    
The discovery of IgE led to the characterization of its receptor. The first identified IgE 
receptor, FcεRI, is present at a high numbers on human and mouse mast cells at ~3-500,000 
receptors per cell and binds IgE with high affinity. It is a tetrameric receptor with α, β, and 2 
disulfide-linked γ subunits in mice and humans. Human mast cells also have a trimeric version 
lacking the β chain that is expressed more broadly on innate immune cells (Figure 2)22. FcεRI 
aggregation, typically via IgE and antigen, induces a biochemical signaling cascade that leads to 
the synthesis and/or release of pro-inflammatory products and modulators of allergic disease 
and parasitic infections.  
The FcεRI β and γ chains contain immunoreceptor tyrosine-based activation motifs 
(ITAMs) with two tyrosine residues. These residues become phosphorylated by Lyn and Fyn 
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after aggregation, serving as docking site for Syk on the γ chains 23. Syk is then activated mainly 
via autophosphorylation, since binding to the ITAMs causes a conformational change increasing 
its enzymatic activity24,25 26. Fully activated Syk then activates the scaffold adaptors LAT1 and 
LAT3 which then activates the PI3K and BTK. Together, this pathway leads to the activation of 
Akt and phospholipase C which hydrolyzes membrane phosphatidylinositol 4,5-triphospate 
(PIP2) in the membrane creating the products diacylglycerol (DAG), which activates protein 
kinase C, and inositol 1,4,5-triphospahte (IP3) which releases ER calcium stores.  ER calcium 
depletion activates the calcium release activated channel (CRAC), which elicits a large calcium 
influx through the cell membrane. This signaling cascade leads to degranulation within minutes 
and is the etiology of the “immediate” allergic response.  
Mast cell cytokine secretion is part of the “late” allergic response that occurs within 
hours. This process is also activated partly by calcium flux with additional signals through 
several kinase cascades including PI3K and MAPK. These converge on transcription factors, 
including NFB, NFAT, AP-1, and Stats. The MAP kinase and PI3K pathways also activate 
phospholipase A2, which cleaves membrane lipids, beginning the synthesis of arachidonic acid 
metabolites. There are also negative regulators involved in controlling this biochemical 
pathway, mainly phosphatases. Lyn can also be involved in negative regulation, giving it a dual 
role27. These integrated pathways are summarized in Figure 322.   
IgE also has a low affinity receptor, CD23, which has an unusual trimeric C-type lectin 
structure. This receptor plays an important regulatory role in the production of IgE, since its 
expression on B cells limits IgE production28. CD23 is cleaved from the membrane by 
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metalloproteases, thus many groups are investigating the inhibition of these metalloproteases 
as a therapeutic option to block the production of IgE.  
In keeping with their innate immunity function, mast cells can also become activated 
independently of IgE. This allows mast cells to participate in physiological processes outside 
allergies and type 2 immunity. In the 1990’s, mast cells were shown to be critical for the 
clearance of bacteria and protection against sepsis through the production of TNF induced by  
bacterial Fimbrial protein 30 31. Mast cells have also been shown to accumulate in response to 
viral infections although their role is not fully elucidated32. In addition to pathogen–associated 
molecular patterns (PAMPs), mast cells respond to damage/danger-associated molecular 
patterns (DAMPs). Via expression of ST2, mast cells respond to the alarmin IL-3333,34. They also 
express P2X receptors which respond to the DAMP extracellular ATP 4,35. Though DAMP-
mediated functions can occur separate from IgE-induced activation, there is now ample 
evidence that DAMPs exacerbate allergic disease partly by enhancing IgE-mediated mast cell 
function36,37. 
 
Allergic Asthma  
 Allergic asthma is characterized by Th2-type lung inflammation, airway remodeling, 
airway hyperresponsiveness, increased mucus production and airway obstruction. The evidence 
for mast cell involvement in asthma includes pulmonary mast cell hyperplasia and high levels of 
leukotrienes, tryptase, chymase, and histamine in the sputum and bronchial alveolar lavage 
fluid of asthmatics38,39–41.  
6 
 
 Anti-IgE treatment is effective in ~60% of asthmatics, supporting the involvement of IgE 
and mast cells in human asthma42. Despite this, earlier reports using mouse models claimed 
that mast cells and IgE are not important for AHR or allergic lung inflammation. However more 
recent reports show that this is highly dependent on the choice of antigen (OVA vs. HDM), 
duration of sensitization, route of sensitization (intraperitoneal vs. intranasal), use of adjuvant, 
and amount of antigen exposure. The use of large amounts of antigen bypasses mast cell 
involvement but this also depends on duration of exposure43. The strain of mice used has also 
been suggested to influence mast cell involvement44.  Although the use of mouse models does 
not fully replicate human disease, these models have contributed to the expansion of our 
knowledge of allergic asthma in the past few decades. With a clearer understanding of how to 
manipulate mouse models to involve most aspects of human asthma, we have more 
information about the role of mast cells in asthma. We know that the  presence of mast cells 
exacerbates AHR and lung inflammation 45 46. Further, eosinophil recruitment is impaired in 
Kitwsh/wsh mice which lack mature mast cells, suggesting that mast cells are important in 
pulmonary eosinophilia47. Mast cell activation causes increased airway hyperresponsiveness to 
methacholine48.  Mast cells have also been shown to possibly control allergic lung 
inflammation, for example the protective role of PGE2 in the lung has been shown to be driven 
through mast cell leukotriene receptors. Overall, the literature and evidence from the clinic 
suggest that mast cells are a viable target for allergic asthma treatment.  
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Purinergic signaling 
 Purinergic signaling involves two subclasses of trimeric receptors, P2X and P2Y. P2X 
receptors are  ligand-gated ionotropic channels, while P2Y are G-protein coupled metabotropic 
receptors. P2X receptors bind ATP, while P2Y proteins interact with ATP and a range of other 
purine-based ligands. There are 7 known P2X receptors (P2X1-P2X7), and 8 P2Y receptors. 
Examining gene knockout (KO) phenotype shows that P2Y receptors have overlapping 
functions, since KOs have mild phenotypes. In contrast, P2X KO mice show prominent 
phenotypes, suggesting unique contributions. P2X7 is the most extensively studied in the 
context of immunity. P2X7 signaling is important for T cell differentiation into Th1 and Th2, 
neutrophil and macrophage migration, synthesis and release of IL-1beta, and inflammasome 
formation49 50 51. P2X2-4 have also been shown to play important immunoregulatory roles. Mice 
deficient in P2X4 had decreased eosinophilia in BAL fluid, as well as decreased Th2 cytokines 
following allergen-induced airway inflammation52 . P2X2 and P2X3 KO mice had increased 
susceptibility to infection and increased immune cell infiltration into the spleen, resulting in 
splenomegaly53. P2X receptors are expressed on most cells of the innate and adaptive immune 
system. Human mast cells have been shown to express mRNA for P2X1, 4 and -74 35. Mast cell 
P2X receptors elicit calcium influx and cytokine/chemokine release upon ligation by ATP4. 
Furthermore, ATP signaling through P2X7 on mast cells was shown to be critical in a murine 
colitis model and human Crohn’s disease through induction of IL-33 release36. These data 
suggest that mast cell purinergic signaling is a viable therapeutic target for allergic disease. 
 P2X3 is more extensively studied in the context of neuropathic pain, although some 
immunological functions have been suggested. For example, colonic tissue has increased P2X3 
expression in patients with inflammatory bowel syndrome54. Also human peripheral blood 
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leukocyte and primary  human B cells have been reported to express P2X3, albeit in smaller 
amounts compared to other P2X receptors55,56. P2X3/P2X2 are commonly known to 
heterodimerize; P2X3/P2X2 DKO mice fail to induce a proper immune response and thus are 
more susceptible to various infections. Human P2X3 has been crystalized, allowing further 
structural insight of this membrane receptor57. Several unique features of P2X3 were revealed 
by this crystallization such as a “cytoplasmic cap” that acts as an anchor in the open/active 
state. This study also revealed that P2X3 needs a Mg2+ binding pocket in close proximity to the 
ATP binding regions. Currently P2X3 antagonists are being investigated for treatment of 
rheumatoid arthritis, chronic pain and refractory cough58,59. There is very little known about 
P2X3 function on mast cells. Our study results suggest that it is positive regulator of IgE- 
mediated mast cell activation.  
    
Selective serotonin reuptake inhibitors  
Selective serotonin reuptake inhibitors (SSRIs) are a class of anti-depressants. Five SSRIs that 
are included in this study are pictured in Figure 4, adopted from the PubChem database. It has 
been noted that anti-depressant use correlates with anti-inflammatory effects. For example, a 
meta-analysis of studies examining serum cytokine levels before and after treatment of 
patients diagnosed with major depressive disorder found that SSRI treatment reduced serum 
TNF and IL-660. A study examining the relationship between depression, SSRI treatment and 
IFNɣ levels in patients with the comorbid diagnoses of major depression and multiple sclerosis 
(MS) found that SSRI treatment led to decreased IFNɣ production, which is corroborated by a 
study showing that SSRI treatment can reduce the onset of experimental MS61 62. Several other 
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studies demonstrate the anti-inflammatory properties of SSRIs63–65. Furthermore, there is 
increasing evidence that blocking inflammatory pathways reduces symptoms of major 
depression and other psychiatric disorders, which can be associated with anti-depressant use. 
This contributes to the evidence of a substantial link between inflammation and depression66 67 
68 69 . More interesting for our work, a trial aimed at studying the safety of administering SSRIs 
to asthmatics found the SSRI group to have decreased need for corticosteroid use, an important 
measure of asthma severity70. This indicates that SSRIs may be a therapeutic option for 
asthmatics. 
 Although these data show that SSRIs have anti-inflammatory effects, the mechanism is 
unclear and could reveal novel drug targets for allergic disease. While SSRIs are designed to 
inhibit the serotonin transporter (SERT), recent work has indicated that paroxetine can inhibit 
P2X7 and P2X471 72. There are also differences between SSRIs. For example, paroxetine can 
inhibit P2X7 but fluoxetine and desipramine cannot73. These data suggest that there is an off-
target effect of SSRIs that is beneficial for asthma treatment and that differences between SSRIs 
could occur.  
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Figure 1 Mast cells contribute to innate as well as adaptive immune responses.  
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Figure 2: IgE and Its High Affinity 
Receptor. IgE binds the alpha chain portion 
of its high affinity receptor at the Fc portion 
of the immunolglobulin. The FcERI is made 
up of an alpha chain, a beta chain and two 
gamma chains. Adopted from Siraganian 
et.al.20 
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Figure 3: IgE Signaling Cascade. The most well studied stimuli of mast cells is through IgE and FcRI. Once IgE on the cell 
surface is crosslinked with antigen, receptor dimerization initiates a signaling cascade requiring of Lyn, Fyn, Syk etc. Signals 
needed for calcium influx and then degranulation occur within minutes. Signals for activation of transcription factors then 
follow and cytokines are transcribed and released within hours of antigen exposure.  
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Fluoxetine Paroxetine 
Citalopram Sertraline 
Fluvoxamine 
Figure 4: SSRI Chemical Structures. Fluoxetine, paroxetine, fluvoxamine, sertraline, and citalopram 
are all selective serotonin reuptake inhibitors. Images adapted from Pubchem database.  
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Chapter 2: Methods 
 
Mouse mast cell culture: 
Bone marrow derived mast cells (BMMCs) were derived from marrow collected from mice 
femurs. Red blood cells were lysed with ACK lysis buffer. Cells were plated in RPMI (Invitrogen 
life technology) with 10% FBS (Sigma), 2mM L-glutamine, 100 U/ml penicillin, 100 ug/ml 
streptomycin, 5ug/ml ciprofloxacin, 1 mM sodium pyruvate and 1mM HEPES buffer. WEHI 
supernatant containing 3ng/mL IL-3, and BHK-MKL supernatant containing 15 ng/mL SCF was 
added to the growth medium. Cells were cultured for 21 days at which point cells were 90% 
cKit/FcRI-positive and ready for experimentation. Peritoneal mast cells (PMCs) were cultured 
the cRPMI with 10 ng/ml IL-3 and SCF for 7-10 days.  
 
Mouse basophil culture: 
Mouse bone marrow-derived basophils were cultured in cRPMI with 20ng/mL recombinant IL-3 
for 7-10 days, and selected for basophils with anti-CD49b (Biolegend clone HMα2).  
 
Mouse eosinophil culture: 
Mouse bone marrow-derived eosinophils were grown in RPMI with Glutamax (Invitrogen), 20% 
FBS, 25mM HEPES, 100 U/mL penicillin, 100ug/mL streptomycin, 1X NEAA, 55 M βME, 
supplemented with 100ng/ml SCF and 100ng/mL FLT-3 (Shenandoah Inc) for 4 days and then 
10ng/mL IL-5 (Shenandoah Inc). On day 12 of culture, cells were 90% SiglecF-positive and 
ready for experimentation74(BD Bioscience clone E50-2440).  
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Human skin mast cells: 
All protocols involving human tissues were approved by the human studies Internal Review 
Board at the University of South Carolina or Virginia Commonwealth University. Cells were 
cultured as previously described75. Human skin mast cells were cultured with 10M fluoxetine, 
1 g/ml mouse IgE, and human recombinant SCF for 24 hours. Cells were washed and re-plated 
with fluoxetine, SCF and 50 ng/ml DNP for 16 hours. Supernatant was collected for cytokine 
analysis by ELISA. 
 
Animals:  
C57BL/6, 129/SvJ, Balb/cJ, and B6.129(Cg)-Slc6a4tm1Kpl/J (SERT KO) mice were purchased from 
Jackson Laboratory, bred and maintained at the VCU animal facilities. All animal care and uses 
were approved by the Virginia Commonwealth University Institutional Animal Care and Use 
Committee (IACUC). All animals in this study were females unless otherwise stated.  
 
Supernatant Cytokine Measurement: 
BMMCs were treated with SSRIs or vehicle at 1x106 cells/mL in cRPMI with 10ng/mL IL3 and SCF 
with 0.5ug/mL anti-DNP IgE for 24 hours. Some experiments were done with pre-sensitized 
BMMCs as indicated in figure legends. Cells were then washed and re-plated with fluoxetine 
and 50ng/mL DNP-HSA for 16 hours. Other BMMCs treated with fluoxetine for 24 hours were 
activated with 150M ATP for 4 hours. Supernatant was collected and analyzed for IL-13, MIP-
1 (CCL-3; Peprotech), IL-6, MCP-1 and TNF (Biolegend) by ELISA as instructed by manufacturer.  
  
16 
 
Degranulation: 
IgE-sensitized BMMCs were treated with fluoxetine for 24 hours, washed, and stimulated with 
50 ng/ml DNP-HSA with fluoxetine present for 30 minutes. Cells were placed on ice and washed 
in ice cold PBS. Cells were stained with anti-CD107a and anti-CD63, then analyzed using a 
FACSCelesta.  
 
RT-qPCR: 
Cells treated +/- fluoxetine were stimulated with IgE crosslinkage as described above for 4 
hours. Trizol (Life Sciences) was used to extract total RNA. Nucleic acid purity was measured 
using a Nanodrop 1000 UV-Vis Spectrophotometer (Thermo Scientific). To measure mRNA 
expression, cDNA was synthesized using the qScript cDNA Synthesis Kit (Quanta Biosciences) 
following the manufacturer’s protocol. qPCR analysis was performed with Bio Rad CFX96 
Touch™ Real-Time PCR Detection System and SYBR® Green detection using a relative Livak 
Method. Reactions consisted of a heat-activation step at 95 °C for 10 min followed by 40 cycles 
of 95 °C for 15s, 55 °C for 30s and 60 °C for 1 min. Fluorescence data were collected during the 
extension step of the reaction. Primers for IL-6 (forward: 5′TCCAGTTGCCTTCTTGGGAC3′, 
reverse: TCCAGTTGCCTTCTTGGGAC3′), β-actin (forward: 5′GATGACGATATCGCTGCGC3′, 
Reverse: 5′CTCGTCACCCACATAGGAGTC3′) and IL-13 (forward: 
ATGGCGTCTGGGTGACTGCAGTCC’, Reverse: GAAGGGGCGTGGCGAAACAGTTGC) were 
purchased from Eurofins.  
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Drugs and Inhibitors: 
Fluoxetine, paroxetine, fluvoxamine, citalopram and sertraline were purchased from Sigma 
Aldrich. Serotonin, RO-3, TCP262, 5BDB, A70003, and NF449 were purchased from Tocris. 
Propidium Iodine exclusion staining of mast cells and flow cytometry was used to determine 
toxicity of all drugs before use. P2X inhibitors were used in the concentration range 
recommended by manufacturer for specificity.  
 
Intracellular Cytokine Staining: 
Basophils or BMMCs were treated with IgE and fluoxetine as previously described, crosslinked 
with DNP-HSA for 2 hours, then treated with 5M monensin for 5 hours. Cells were fixed in 4% 
paraformaldehyde for 20 minutes at room temperature and stored in PBS overnight at 4C. The 
next day, fixed cells were permeabilized in saponin buffer for 20 minutes at room temperature 
and then stained in saponin buffer at 4C for 40-60 minutes with fluorochrome-labeled anti-IL6 
( BD Bioscience clones MP5-20F3), anti-TNF (BD Bioscience clone MP6-XT22), anti-MCP 
(Biolegend clone 2H5), anti-IL4 (BD Bioscience clone 11B11  or anti-IL13 (BD Bioscience JES10-
5A2).  
 
Mass Spectrometry for Lipid Detection: 
BMMCs were treated with IgE and fluoxetine as previously described and activated with 
50ng/mL DNP-HSA or 150M ATP for 1 hour. Supernatant were stored at − 80 °C until the time 
of analysis. Lipids were extracted for eicosanoids. Eicosanoid Preparation-Eicosanoids were 
extracted using a modified extraction process from previously described76,77. 4 mL of media was 
combined with an IS mixture comprised of comprised of 10% methanol (400 μl), glacial acetic 
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acid (20 μl), and internal standard (20 μl) containing the following deuterated eicosanoids (1.5 
pmol/μl, 30 pmol total) (All standards purchased from Cayman Chemicals): (d4) 6keto-
Prostaglandin F1α, (d4) Prostaglandin F2α, (d4) Prostaglandin E2, (d4) Prostaglandin D2, (d8) 5-
Hydroxyeicosa-tetranoic acid (5-HETE), (d8) 12-Hydroxyeicosa-tetranoic acid (12-HETE) (d8) 15-
Hydroxyeicosa-tetranoic acid (15-HETE), (d6) 20-Hydroxyeicosa-tetranoic acid (20-HETE), (d11) 
8,9 Epoxyeicosa-trienoic acid, (d8) 14,15 Epoxyeicosa-trienoic acid, (d8) Arachidonic acid, (d5) 
Eicosapentaenoic acid, (d5) Docosahexaenoic acid, (d4) Prostaglandin A2, (d4) Leukotriene B4, 
(d4) Leukotriene C4, (d4) Leukotriene D4, (d4) Leukotriene E4, (d5) 5(S),6(R)-Lipoxin A4, (d11) 5-
iPF2α-VI, (d4) 8-iso Prostaglandin F2α, (d11) (±)14,15-DHET, (d11) (±)8,9-DHET, (d11) (±)11,12-
DHET, (d4) Prostaglandin E1, (d4) Thromboxane B2, (d6) dihmo gamma linoleic acid, (d5) 
Resolvin D2, (d5) Resolvin D1, (d5) Maresin 2, and (d5) Resolvin D3. Samples and vial rinses (5% 
MeOH; 2 ml) were applied to Strata-X SPE columns (Phenomenex), previously washed with 
methanol (2 ml) and then dH2O (2 ml). Eicosanoids eluted with isopropanol (2 ml), were dried 
in vacuuo and reconstituted in EtOH:dH2O (50:50;100 μl) prior to UPLC ESI-MS/MS analysis. 
Liquid chromatography/mass spectrometry: Analysis of Eicosanoids by UPLC ESI-MS/MS-
Eicosanoids were separated using a Shimadzu Nexera X2 LC-30AD coupled to a SIL-30AC auto 
injector, coupled to a DGU-20A5R degassing unit in the following way. A 14 min. reversed phase 
LC method utilizing an Acentis Express C18 column (150mm x 2.1mm, 2.7µm) was used to 
separate the eicosanoids at a 0.5 ml/min flow rate at 40°C. The column was equilibrated with 
100% Solvent A [acetonitrile:water:formic acid (20:80:0.02, v/v/v)] for 5 min and then 10 µl of 
sample was injected. 100% Solvent A was used for the first two minutes of elution. Solvent B 
[acetonitrile:isopropanol:formic acid (20:80:0.02, v/v/v)] was increased in a linear gradient to 
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25% Solvent B at 3 min., to 30% at 6min., to 55% at 6.1min., to 70% at 10 min., to 100% at 
10.10min., 100% Solvent B was held constant until 13.0min, where it was decreased to 0% 
Solvent B and 100% Solvent A from 13.0min to 13.1min. From 13.1min to 14.0 min. Solvent A 
was held constant at 100%. Eicosanoids were analyzed via mass spec using an AB Sciex Triple 
Quad 5500 Mass Spectrometer. Q1 and Q3 were set to detect distinctive precursor and product 
ion pairs. Ions were fragmented in Q2 using N2 gas for collisionally-induced dissociation. 
Analysis used multiple-reaction monitoring in negative-ion mode. Eicosanoids were monitored 
using precursor → product MRM pairs, which can be found in Supplementary Table S5. The 
mass spectrometer parameters used were: Curtain Gas: 20 psi; CAD: Medium; Ion Spray 
Voltage: -4500 V; Temperature: 300 °C; Gas 1: 40 psi; Gas 2: 60 psi; Declustering Potential, 
Collision Energy, and Cell Exit Potential vary per transition. 
 
Passive Systemic Anaphylaxis: 
Female mice were sensitized with 50g IgE and treated with PBS or fluoxetine at 1mg/Kg 
intraperitoneally. The next day, mice were given a second injection of PBS or fluoxetine. Base 
core body temperature using rectal thermometer (Braintree Scientific Inc) was recorded. 2 
hours later mice received 100g DNP-HAS by IP injection. Core body temperature was recorded 
every 10 minutes for 1 hour and then every 30 minutes for 1 hour for a total of 2 hours. Mice 
were sacrificed using CO2 asphyxiation as approved by the VCU IACUC. Peritoneal lavage was 
collected with PBS+5mM EDTA and cardiac puncture was performed. Lavage cells were stained 
with Zombie aqua dye (Biolegend), anti-CD45 (BD Bioscience clone 30-F11), anti-cKit (BD 
Bioscience clone ACK45), and anti-FcεRI (Biolegend clone MAR-1). Cell counts were determined 
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by Precision Counting Beads (BD) by manufacturer’s instructions. Plasma cytokine levels were 
determined using IL-13 and MIP-1 ELISA kits from Peptrotech, and IL-6 ELISA kit from Biolegend. 
Plasma histamine levels were determined using Neogen Histamine Kit. Histamine-induced 
anaphylaxis was elicited by IP injection of 5mg histamine. 
 
Flow Cytometry: 
For direct surface markers, cells were blocked with anti-CD16/CD32 clone 2.4G2 and stained at 
4C for 20-30 minutes. For intracellular staining, Cells were fixed in 4% formaldehyde at room 
temperature for 30 minutes and stored overnight in PBS at 4C . The next day, cells were 
permeabilized with saponin buffer for 20 minutes and stained with rabbit anti-P2X3 (Novus 
Biologicals LLC NB100-1654 or Abcam ab90905) or rabbit isotype IgG, then washed and stained 
with PE-coupled Donkey anti-rabbit IgG (Biolegend). All flow data was acquired using 
FACSCelesta and analyzed by FACS Diva or FlowJo software. Flow cytometry with BMMCs were 
gated on high FSC and SSC and singlets. Further gates are determined using isotype and FMO 
controls.   
 
Intracellular Calcium Flux Assay: 
BMMCs were treated -/+ fluoxetine and IgE for 24 hours. Cells were washed and loaded with 
fura2 AM (Thermofisher) at 37C for 40 minutes. Cells were washed and plated in Tyrode’s 
buffer with 1% FBS, 10ng/mL IL-3 and SCF -/+ fluoxetine. Cells were allowed to rest at room 
temperature for 30 minutes and 37C for 10 minutes. Cells were activated with 150M ATP, 
50ng/mL DNP-HSA or 10M ionomycin. Some samples received DNP-HSA and fluoxetine 
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together. Cells were analyzed using a Flexstation plate reader (Molecular Devices). Data were 
collected every 4 seconds and reported as a ratio of 340/380 nm excitation detected at 510 nm 
emission.  
NFκB reporter activity: 
006100 - B10.Cg-H2k Tg(NFkB/Fos-luc)26Rinc/J mice from Jackson Laboratory were used to generate 
NFκB reporter BMMCs as described above. BMMCs were treated with fluoxetine and activated with 
150µM ATP for 2 hours. Cells were lysed and luciferase activity was measured with the Promega 
Luciferase Assay Substrate and Glomax 20/20 Luminometer (Promega). Luciferase expression is 
normalized to the unactivated control. 
 
siRNA Knock Down Experiments: 
BMMCs were growth factor starved for 3 hours. 10ng/mL IL3 and SCF was added 16 hours prior 
to transfection. For transfection, 3 million cells were spun down, resuspended in 100uL 
transfection media (DMEM, 20% FBS, 50mM HEPES)+ 2uM siRNA (scramble control, P2X7, SERT 
or P2X3 specific siRNA purchased from Qiagen), placed in transfection cuvette and 
electroporated in program T-05 in the Amaxa instrument. Cells were plated at 0.5X105 cells/mL 
and allowed to rest for 48 hours in cRMPI+10ng/mL IL3 and SCF. At 48 hours, cells were 
collected to check knock down efficiency by protein staining via flow cytometry (P2X7 antibody 
-Biolegend clone 1F11, SERT antibody-Alomone Labs cat# AMT-004). Cells were spun down in 
fresh media, sensitized with IgE, treated with fluoxetine at various doses and crosslinked as 
previously described.   
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Western Blot: 
BMMCs were treated with fluoxetine and crosslinked as described earlier. After crosslinking for 
0 or 15 minutes, cells were lysed.  Western blotting was performed using 50μg of total protein 
per sample. Protein was loaded and separated over 4–20% gradient SDS polyacrylamide gels 
(Bio–Rad, Hercules, CA). Proteins were transferred to nitrocellulose (Pall Corporation, Ann 
Arbor, MI), and blocked for 60 minutes in 1% Blocker Casein (Thermofisher) in TBS plus 0.1% 
Tween 20 (TBST). Blots were incubated in Casein/TBST with a 1:1000 dilution of anti-Syk, pSyk, 
AKT, pAKT (Cell Signaling) overnight at 4°C with gentle rocking. Blots were washed six times for 
10 minutes each in TBST, followed by incubation in Blocker Casein containing at 1:5000 dilution 
of fluorescently –labeled anti–IgG (matched to the appropriate primary antibody source 
species, from Cell Signaling, Danvers, MA). Size estimates for proteins were obtained using 
molecular weight standards from Bio–Rad. Blots were visualized and quantified using a LiCor 
Odyssey CLx Infrared imaging system.  Fluorescence intensity for the protein of interest was 
normalized to the signal intensity for the relevant loading control, using Image Studio 4.0 (Li-
Cor). 
HDM Sensitization, Airway Hypersensitivity and Lung Inflammation Model:  
Female C57BL/6J mice were sensitized with 50g HDM (Stallergenes Greer Cat# XPB70D3A2.5, 
Lot 360924) in 4mg Imject Alum (Thermofisher) daily on days 0-2. Starting on day 13, every 3 
days, mice were given 25g HDM intranasally, under isoflurane anesthesia. Mice were given 
PBS or fluoxetine dissolved in PBS on days 11-23 intranasally. On day 24, mice were 
anesthetized and a cannula was inserted in the trachea. Mice were then subjected to forced 
oscillation on a computer controlled ventilator (Flexivent system, Scireq Inc.) during increasing 
nebulized methacholine exposure. BALF was collected for cytokine ELISA and cells were 
23 
 
analyzed by flow cytometry. Lung lobes were either flash frozen for RNA collection, or digested 
and single cell suspension was stained for flow cytometry, or fixed in 10% formalin for H&E and 
PAS staining. For flow cytometry analysis, all cells were stained with Zombie aqua dye, blocked 
with 2.4G2, and stained with anti-CD45, anti-FcRI, and anti-cKit for mast cells; anti-CD90.2 
(Biolegend clone 30-H12)for T cells; anti-B220 (BD Bioscience clone RA3-6B2) and anti-MCH II 
(BD Bioscience clone M5/114) for B cells; anti-SiglecF and anti-CCR3 (Biolegend J073E5) for 
eosinophils; anti-CD3 (BD Bioscience clone 17A2), anti-CD4 (Biolegend clone  GK1.5), anti-IL4, 
and anti-IL13 for Th2 cells; or anti-CD11b (Biolegend clone M1/70) and anti-Ly6G(BD Bioscience 
clone 1A8) for neutrophils. Cell number was determined using Precision Counting Beads as 
directed by the manufacturer (BD). For re-stimulation, lung cells were plated in cRPMI with 
1M ionomycin, 25ng/mL PMA and 5M monensin at 37C for 3 hours prior to staining. All 
gating was determined by isotype and fluorescence minus one control. Initial gating strategy 
shown in figure 21B. Th2 cells gated on CD3+CD4+ cells. Blood plasma was collected for total 
IgE (Biolegend) and HDM-IgG (Condrex) by ELISA.  
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Chapter 3: Results 
 
SSRIs Suppress IgE-mediated cytokine production in BMMCs and PMCs  
 SSRIs have been shown to suppress LPS-mediated TNF production in macrophages 65 64. We 
first tested a panel of SSRIs for effects on mast cell IgE-induced cytokine production (Fig. 4). The 
drug concentrations were the highest that did not affect viability of C57BL/6J BMMCs, as 
measured by PI exclusion. All 5 SSRIs suppressed cytokine production to varying degrees, with 
citalopram being the least suppressive and paroxetine the most suppressive.  
Inbred laboratory mice are highly genetically variable across strains78. To test the 
genotypic effect on the suppression induced by SSRIs, the experiment was repeated with 
BMMCs derived from BALB/cJ and 129S1/SvImJ strains (Fig. 5). 2 out of 5 SSRIs suppressed 
cytokine production regardless of mice strain background. Overall, citalopram appeared to be 
the least suppressive and even increased cytokine production in the BALB/cJ background. 
Fluvoxamine and sertraline were also not consistently suppressive in the C57BL/6J and Balb/cJ 
backgrounds respectively. Therefore, we continued to do further experimentation with 
paroxetine and fluoxetine. Paroxetine did not alter degranulation in vitro or in vivo (data not 
shown), therefore we focused on fluoxetine.  
To determine the kinetics of fluoxetine effects, a time course was performed (Figure 
6A). Fluoxetine significantly suppressed TNF production starting at 1 hour and up to 7 days of 
pretreatment. To determine optimal dosage, a dose response was performed using a 24-hour 
pretreatment period (Figure. 6B). At least 10M fluoxetine was needed to suppress IgE-
mediated cytokine secretion. This is a clinically relevant dosage for humans because tissue 
concentrations of fluoxetine up to 60 M have been reported in adults, although blood 
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concentrations are much lower, typically reported at 1-2uM79,80. Since mast cells are tissue 
resident cells, the tissue concentrations are more relevant in this case. These conditions did not 
affect BMMC viability (Figure 6C).  
To begin determining how fluoxetine suppresses cytokine secretion, we measured 
intracellular IL-6 by flow cytometry. As with secretion, IgE-mediated cellular IL-6 was also 
suppressed by fluoxetine (Figure 7A). We then assessed cytokine gene transcription by 
performing RT-qPCR for IL-6 and IL-13 mRNAs (Figure 7B). Since the induction of both cytokine 
mRNAs was suppressed, we hypothesize that fluoxetine-mediated suppression is at a 
transcriptional level.  
Mast cell activation is multi-phasic. The late phase response includes release of newly 
formed mediators such as cytokines measured in Figure 4. The early phase response involves 
the release of pre-formed mediators, most of which are stored in granules. The process of 
degranulation is rapid, occurring within minutes. We tested whether fluoxetine suppresses IgE-
mediated degranulation. BMMCs were treated with 10M fluoxetine for 24 hours, and IgE 
crosslinked (IgE XL) for 30 minutes. The cells were then surface-stained with anti-CD107a, a 
lysosomal marker whose cell surface expression corresponds to degranulation, and analyzed by 
flow cytometry (Figure 8A). Both the percent CD107a positive and the MFI were suppressed by 
fluoxetine treatment. Because degranulation is dependent on calcium influx, we tested if this 
early activation event was also altered by fluoxetine (Figure 8B). We found that pretreatment 
with fluoxetine significantly suppressed intracellular calcium levels. Moreover, we found that 
cells exposed to fluoxetine simultaneously with antigen showed a greater reduction of calcium 
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influx. These data indicate a mechanism of action that is both rapid and suppresses early FcRI 
signaling events. 
Mast cells produce large amounts of eicosanoids that contribute to chemotaxis and 
vasodilation. Thus we measured lipids by mass spectrometry 1 hour after IgE-XL. Twenty-five 
lipids were detected. Fourteen were induced by IgE XL, of which eight were altered by 
fluoxetine treatment (Figure 9A). The eicosanoids induced by IgE XL but not suppressed by 
fluoxetine treatment are shown in Figure 9B. We postulate that these divergent effects may be 
due to selective fluoxetine effects on the enzymes involved in arachidonic acid metabolism.  
Peritoneal mast cells (PMCs) are differentiated in vivo and thus provide a tool to test 
whether the effects of fluoxetine on BMMCs are tied to in vitro maturation. PMCs were IgE 
sensitized and treated with fluoxetine as in Figure 4 for cytokine measurement or as in Figure 7 
to assess degranulation (Fig. 10A-B). Fluoxetine suppressed both cytokine production and 
degranulation in PMC cultures, suggesting that these effects are not linked to in vitro 
maturation.  
One explanation for reduced IgE-mediated function is reduced expression of FcRI or c-
Kit, which augments its signaling81–83 . Therefore, we measured surface FcRI and c-Kit with or 
without fluoxetine treatment (Figure 11). Fluoxetine did not alter c-Kit and unexpectedly 
increased FcRI expression. Therefore, reduced receptor expression is not a mechanism of 
action. Measuring the signaling cascade downstream of FcεRI, we found that phosphorylation 
of Syk, Btk, Akt, Erk and STAT5 were decreased by fluoxetine. Overall, these data establish that 
fluoxetine suppresses early and late phase IgE-mediated mast cell activation in vitro and ex vivo, 
and this affects proximal FcεRI signaling events. 
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Extracellular serotonin or the serotonin transporter is not involved in fluoxetine’s 
mechanism 
Mast cells can produce serotonin, express several serotonin receptors and the serotonin 
reuptake transporter (SERT)84. Since fluoxetine is a SERT inhibitor, we determined if increased 
extracellular serotonin or SERT expression is involved in suppressing mast cell function. BMMCs 
were treated with increasing doses of recombinant mouse serotonin prior to IgE XL. This had no 
effect on cytokine production (Fig 12). We then tested the involvement of SERT by performing a 
fluoxetine dose response in SERT deficient (KO) BMMCs (Fig 13A) and in SERT knock down (KD) 
BMMCs (Fig 14). Both the KO and KD responded to fluoxetine similarly to the control BMMCs, 
thus SERT expression is not required for fluoxetine-mediated suppression. Mast cell surface 
markers were analyzed, and no differences were found between WT and SERT KO mast cells for 
surface FcRI or c-Kit expression (Fig 13B) 
 
P2X3 is expressed on BMMCs and is necessary for fluoxetine induced suppression 
It has been previously reported that other drugs of the SSRI class can suppress P2X 
receptors. Since these receptors are expressed on mast cells, we hypothesized that they are a 
functional target of fluoxetine71,73. We first tested if chemical inhibition of P2X1, 3, 4, or 7 alters 
IgE-mediated cytokine production and found that P2X3 inhibition via two different chemicals 
caused a marked decrease in cytokine production (Figure 15). Although P2X7 inhibition did not 
significantly suppress cytokine production, it trended lower. To test if fluoxetine is targeting 
either P2X7 or P2X3, fluoxetine dose response was done on BMMCs after siRNA knock down of 
either gene (Figure 16A). We found that P2X7 KD had no effect on fluoxetine’s ability to 
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suppress IgE-induced cytokine production, while P2X3 inhibition greatly reduced fluoxetine 
effects. This suggests that fluoxetine is acting through P2X3 antagonism. A possible mechanism 
is downregulation of this receptor. We tested if fluoxetine treatment alters P2X3 expression 
and found that after 24 hours of fluoxetine treatment, P2X3 expression is significantly 
decreased (Figure 16B). Since simultaneous addition of fluoxetine and antigen caused 
significant suppression of early FcRI signaling, we hypothesize that fluoxetine is suppressing 
P2X3 function as well as expression. 
 
Fluoxetine suppresses ATP-induced mast cell activation 
ATP is a well-recognized DAMP signal85. Recent reports have shown that ATP can also act as a 
positive feedback regulator in inflammatory states. For example, it has been shown that mice 
deficient in ecto-nuclease expression have exacerbated allergic lung inflammation and allergic 
dermatitis86 87. These effects have been linked to ecto-nuclease expression on mast cell and 
basophil surface. Mechanistic work has shown that other innate cell types, such as eosinophils 
have an autocrine LPS-ATP loop88. To test for the possibility of an ATP autocrine loop in mast 
cells, ATP release was measured after IgE XL. We found a rapid release of ATP in the first 
minute of XL (Fig 17). Furthermore, the addition of recombinant CD39 ATPase at the time of 
stimulation reduced IgE-mediated cytokine secretion. Collectively, these data suggest that IgE 
XL elicits rapid ATP release that enhances mast cell activation. 
Since extracellular ATP has been reported to induce mast cell activation through P2X 
receptors 4,86,87, we tested if fluoxetine can inhibit this antigen-independent activation. 
Fluoxetine suppressed ATP-mediated calcium influx, degranulation, lipid production, NFB 
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activity, and IL-6 production (Fig 18 C-E). These data are consistent with the theory that 
fluoxetine effects could be mediated by antagonizing ATP-mediated mast cell activation 
downstream of FcRI signaling.  
To understand the role of P2X3 in IgE mediated signaling, we next examined IgE- 
mediated Syk phosphorylation after treating BMMCs with P2X3 inhibitors. We found that two 
different chemical inhibitors of P2X3 suppressed IgE-induced Syk phosphorylation (Figure 19). 
This suggests a role for P2X3 in the early signaling events downstream FcεRI and further 
supports our hypothesis.  
Fluoxetine suppresses mast cell-dependent anaphylaxis in vivo 
Since fluoxetine suppressed mast cells in vitro and ex vivo, we next examined in vivo 
relevance. Female C57BL/6J mice were passively sensitized with anti-DNP IgE and treated with 
saline or fluoxetine by IP injection. A second injection of PBS or fluoxetine was given 16 hours 
later, followed by antigen injection after 2 hours. Body temperature was collected every 10 
minutes (Figure 20A). Mice were sacrificed after 15 minutes to measure plasma histamine 
(Figure 20B), or 2 hours to measure plasma cytokines (Figure 20C). We also subjected mice to 
histamine-induced anaphylaxis to test if fluoxetine is affecting the vasculature response to 
histamine, instead of acting directly on mast cells. Mice treated with PBS or fluoxetine show the 
same response to histamine, suggesting that the suppressive effect is directly on mast cells 
rather than vasculature (Figure 20F).  Thus far, our data show that multiple parameters of mast 
cell activation are suppressed by fluoxetine, in vitro and in vivo.  
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Fluoxetine suppresses HDM-induced lung AHR and inflammation 
Next we tested fluoxetine effects in an HDM-induced allergic lung inflammation model 
that mimics some aspects of human asthma. Mice were sensitized to HDM in alum 
intraperitoneally daily for three days. Starting on day 13, they were exposed to HDM 
intranasally every three days. On days 11-22 the mice received PBS with or without fluoxetine 
intranasally daily (Figure 21A). Sensitized mice treated with fluoxetine had significantly 
decreased methacholine-induced airway responsiveness as measured by resistance (Rrs) and 
elastance (Ers). Pulmonary mast cells were found in increasing number and percentage in HDM-
sensitized mice, an effect that was significantly reduced by fluoxetine (Figure 21B). A hallmark 
of HDM lung inflammation is increased eosinophils in the BALF and lung tissue. We measured 
eosinophils in the lung tissue and found that HDM did increase the number and percent of 
eosinophils as expected. Fluoxetine treatment significantly suppressed eosinophil recruitment 
to the lungs (Figure 21C). The overall number or percentage of lung T cells did not change with 
HDM sensitization, but IL-4/IL-13 producing T cells increased in the HDM PBS group, an effect 
that was also reduced by fluoxetine. In addition to pulmonary tissues, BALF analysis showed 
that eosinophils, neutrophils, T and B cells were recruited to the bronchoalveolar space in mice 
sensitized with HDM. Fluoxetine treatment blocked all cell recruitment (Figure 21E-G). BALF 
cytokine analysis also showed significant suppression of IL-5, MIP-1, IL-13, IL-4, IL-6 and MCP-1 
in fluoxetine-treated versus PBS-treated mice (Figure 21H). Total IgE and anti-HDM IgG were 
increased in HDM-sensitized mice, with no difference between PBS- and fluoxetine-treated 
groups. This was likely because fluoxetine treatment was not begun until mice were sensitized, 
and demonstrates that even without suppressing the B cell response fluoxetine can be 
beneficial in established allergic disease (Figure 21I).  
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Fluoxetine and other innate immune cells  
Fluoxetine effects in the HDM-induced lung model suggest that fluoxetine can suppress 
other cell types. We tested fluoxetine on murine bone marrow derived basophils and 
eosinophils (Figures 22 and 23). Fluoxetine suppressed IgE-induced cytokine production in 
basophils inconsistently, with no changes observed in IL-4 and IL-6 production and only slight 
suppression of TNF and IL-13 expression (Figure 22A). There was a consistent suppression of 
CD49b expression after 24 hours pretreatment of fluoxetine, suggesting fluoxetine may 
interfere with basophil maturation (Figure 22B). Further, we did not detect P2X3 expression on 
mouse bone marrow derived basophils, but they did express P2X7, as previously shown by 
other groups (Figure 22C)86. The lack of P2X3 expression may explain the limited fluoxetine 
effects on basophil function. An elucidation on the decreased CD49b expression requires 
further investigation since it is most probable to occur through a mechanism independent of 
P2X3 receptor.  
We show that fluoxetine can suppress ATP-induced eosinophil degranulation (Fig 23A). 
Fluoxetine also decreased CCR3 expression on eosinophils (Fig 23B). CCR3 is the chemotaxis 
receptor eotaxin-1 (CCL11)89 90 and has been shown to be important for eosinophil recruitment 
to the lungs and intestine during type 2 inflammation91 92. The decreased expression of CCR3 
may help explain reduced eosinophilia in the mouse HDM lung inflammation model.  ATP- 
induced cytokine production from eosinophils was undetectable. It is unknown whether 
eosinophils express P2X3.  
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Fluoxetine suppresses human mast cells, human mast cells express P2X3 
Finally, we corroborated our mouse studies by testing fluoxetine effects on human skin 
derived mast cells (HuMC; Figure 24.) IgE-induced cytokine production by HuMC from 5 donors 
was significantly suppressed by fluoxetine. We measured P2X3 on human skin mast cells and 
show that this receptor is expressed. Like our data with mouse mast cells, fluoxetine treatment 
downregulated P2X3 expression on human skin cells as well (Figure 24). It has previously been 
reported that P2X7 receptor expression is heterogenous between mast cells depending on the 
tissue of maturation. For example, skin mast cells lack P2X7, but intestinal mast cells express it 
abundantly87. Thus more studies need to be done to determine the heterogeneity of P2X3 
expression on mast cells. These initial findings show that skin-derived mast cells can be 
suppressed by fluoxetine, supporting further study of this SSRI for its ability to reduce allergic 
inflammation.  
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Figures 
 
  
Figure 4 Panel of SSRIs suppress C57BL/6 BMMCs:  A) BMMC, pre-sensitized with 
Dinitrophenyl (DNP)-specific IgE, were cultured in cRPMI + IL-3/SCF (10ηg/ml) with 
fluoxetine=fluox (10μM), sertraline=sertra (2μM), fluvoxamine=flovox(8μM), 
paroxetine=parox (5μM), citalopram=citalo(30μM) or vehicles, for 24hrs. DNP was added at 
50ηg/ml for 16hrs. IgE XL= IgE-DNP crosslinked. Supernatant cytokines were measured by 
ELISA. Data shown are representative of two independent experiments in triplicates. 
Statistical value determined by ANOVA comparing each drug to its respective crosslinked 
vehicle control (Dunnet test). *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 5: SSRIs Tested on 
Balb/c and 129/sv BMMCs. 
BMMCs were derived from 
129S1/Sv (left) or BALB/cJ (right) 
mice and treated as in 4A. Data 
shown are representative of two 
independent experiments in 
triplicates. Statistical value 
determined by ANOVA, 
comparing each drug to its 
respective crosslinked vehicle 
control (Dunnet test). *p<.0332; 
**p<.0021;*** <.0002 
****p<.0001. No asterisk or 
NS=not significant. 
 
                 129/SV                                                     BALB/c                
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Figure 6 Fluoxetine Kinetics and Viability: A) BMMCs were treated with 10M fluoxetine for the indicated time points 
pre-cross linkage. For time points longer than 24 hours, cells were washed and plated with fresh fluoxetine every 2 days. 24 
hours before IgE XL, cells received IgE, overnight. The cells were washed and re-plated with fresh fluoxetine, and DNP-HSA 
was added to crosslink for 16 hours. Fluoxetine treated group is compared to its media control for statistics. B) Cells were 
treated as in A for 24 hours with 20, 10, 5, 2.5 or 0 M fluoxetine, cells were collected for PI exclusion in (C) and 
supernatant was used for cytokine analysis with ELISA. Each timepoint is compared to crosslinked untreated control for 
statistics. All experiments represented of 2 or 3 independent repeats done with triplicates. Statistical value determined by 
One-way ANOVA (Dunnet test). *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 7 Intracellular and mRNA cytokine levels: A)Fluoxetine-treated BMMCs were 
activated by IgE XL for 2 hours, treated with monensin for 5 hours, then fixed in 
paraformaldehyde, permeabilized in saponin buffer, stained for intracellular IL-6 and analyzed 
by FACSCelesta. Data are from 1 experiment done in triplicate. B) Fluoxetine-treated BMMCs 
were crosslinked for 4 hours and RNA was collected using Trizol. Ct values are normalized to 
actin controls. Data is pooled from two independent experiments done in triplicate. Statistical 
value determined by One-way ANOVA. *p<.0332; **p<.0021;***p<.0002; ****p<.0001 
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Figure 8 Fluoxetine Suppresses IgE-mediated Degranulation and Calcium Influx: A) BMMCs were 
treated with fluoxetine at 10M for 24 hours, then activated by IgE XL for 30min. Cells were stained for 
CD107a and analyzed by FACSCelesta. Data are representative of three independent experiments done in 
triplicate. B) Cells were treated as in (A), loaded with fura2 for 40 min at 37 degrees, washed and plated in 
96-well plates. Cells were allowed to rest at room temp for 30 min and then at 37 degrees for 10 min prior 
to activation. Cells were activated and analyzed by Flexstation plate reader every 4 seconds. Data were 
collected for a minute to establish baseline, then cells were activated with DNP alone or DNP+fluoxetine for 
360 seconds.  Data are pooled from 2 independent experiment done in triplicate. Statistical value 
determined by ANOVA and AUC. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 9 Fluoxetine Suppresses IgE-induced Inflammatory Lipid Secretion: Fluoxetine-treated 
BMMCs were IgE crosslinked for 1 hour and supernatant was analyzed for eicosanoid production by 
mass spectrometry. Data are pmole/4 million cells. A) Heat-map represents mean of lipids from 3 
populations. B) Lipids that are induced by IgE XL and altered by fluoxetine treatment. Data are 
representative of two independent experiments done in triplicate. Statistical value determined by one-
way ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 9C Fluoxetine Suppresses IgE-induced Inflammatory Lipid Secretion: Lipids from figure 
9A, that are induced by IgE XL but not altered by fluoxetine treatment. Statistical value determined by 
one-way ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 10 Peritoneal Derived Mast cells: PMCs were treated as described for BMMC for cytokine analysis, (A), or 
degranulation analysis, (B). Data in (A) are a representative of two independent experiments done with PMCs from3- 5 
animals per experiment. (B) is pooled data from two independent experiments done with PMCs from 4 or 5 animals per 
experiment. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 11 Fluoxetine Suppresses IgE induced signaling:  Surface receptors were stained after 24 
hour treatment of fluoxetine at 10M. Data are from a single experiment done in triplicate. BMMCs were 
treated with fluoxetine and IgE for 24 hours, washed, and crosslinked in the presence of fluoxetine, for 10 
mins. Activation was stopped with the addition of paraformaldehyde. Cells were permeabilized with 
methanol, stored in 4 degrees overnight and stained and analyzed by FACScelesta. Western blot cell 
lysates were obtained from cells treated the same way.  Data are representative of two independent 
experiments done in triplicates. Statistical value determined by unpaired student t-Test for surface 
markers, one way ANOVA for phosphor-proteins. *p<.05; **p<.001; ****p<.0001 for t-Test. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 for one-way ANOVA 
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Figure 12 Serotonin pretreatment of BMMCs:  BMMCs pre-sensitized with IgE were treated with 0, 50, 
100 or 400 ng/ml of recombinant mouse serotonin for 24 hours, crosslinked and supernatant was analyzed for 
cytokine by ELISA. Data are representative of 4 independent experiments done in triplicates. Statistical value 
determined by one-way ANOVA.NS=not significant  
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Figure 13 Fluoxetine Dose Response on SERT Deficient BMMCs. A)BMMCs were derived from WT and 
SERT KO mice. Cells were presensitized with IgE and fluoxetine dose response was performed. Cells were 
activated for 16 hours and supernatant was collected for cytokine analysis.B) Surface staining by 
FACSCelesta. Data is pooled from 3 independent experiments done in triplicates. Statistical value determined 
by ANOVA or student T test in (B). 
A. B. 
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Figure 14 Fluoxetine dose response on siRNA induced SERT KD BMMCs. BMMCs were 
transfected with scramble control and SERT specific siRNA. 72 hours later, KD efficiency was determined 
by flow cytometry and cells were sensitized with IgE overnight. The next day, a dose response was done 
with fluoxetine for 24 hours and cells were activated for 16 hours. Data is pooled from 3 independent 
repeats done in triplicates. Statistical value determined by one way ANOVA. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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Figure 15 P2X Inhibitor Effects on cytokine production in BMMCs. BMMCs were sensitized with IgE overnight, and 
treated with NF449, 5BDB, A70003, TCP262 (10uM), and RO-3(7.5uM) for 24 hours and then treated with DNP for 16 hours. 
Data are pooled from 2 independent experiments done in triplicates. Statistical value determined by ANOVA. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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Figure 16 Fluoxetine dose response on P2X7 or P2X3 knock down BMMCs.  BMMCs were transfected 
with scramble control, P2X7 or P2X3 specific siRNA. KD efficiency was determined 72 hour post transfection. 
Cells were treated as in figure 14. Data is representative of 3 independent experiments done in triplicate. 
Statistical value determined by ANOVA or student T test for protein expression. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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Figure 16B P2X3 Expression on BMMCs after fluoxetine treatment. BMMCs were treated with 
10uM fluoxetine for 24 hours and stained for P2X3 by flow cytometry. Data is from 1 experiment with 
three populations, in duplicates. Statistical value determined by ANOVA. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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A. B. 
 
Figure 17 IgE induced ATP release and ATPase effects on IgE induced cytokine 
production. A) BMMCs were sensitized with IgE overnight, activated for 60 seconds and the cells 
were filtered out of the supernatant. ATP was measured using a luminescent ATP measuring kit. 
B) BMMCs were sensitized with IgE overnight, and activated with or without CD39 for 16 hours. 
Supernantant was collected for ELISA for cytokine measurement. Data is pooled from 2 
independent experiments.  Statistical value determined by ANOVA. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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Figure 18 Fluoxetine Suppresses ATP mediated BMMC Activation. BMMCs were treated with 10µM 
fluoxetine for 24 hours and activated with 300µM ATP  for calcium influx, A, for 15 minutes for degranulation, B , 
150µM for 1 hour for lipid production, 2 hour for reporter activity, 4 hours for IL-6 production, E. A,B,D,E are 
pooled from two or more independent experiments done in triplicates. C is a representative of 2 independent 
experiment done in triplicate or quadruplicates. Statistical value determined by ANOVA. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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Figure 19 P2X3 Inhibition Suppresses phosphorylation of Syk. IgE sensitized BMMCs were treated with 
RO-3 (7.5uM) or TCP262 (1uM) for 1 or 24 hours before IgE cross linkage. P-Syk was measured by flow 
cytometry. Black histogram plot represents IgE XL Vehicle, blue histogram plot represents IgE XL inhibitor 
treated. Data is representative of two independent experiments done in triplicates. Statistical value determined 
by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 20 Fluoxetine Suppress Mast cell function in vivo.  Mice were sensitized with DNP-IgE i.p. and 
treated with PBS or fluoxetine. The next day mice received a second dose of PBS or fluoxetine. 2 hours later 
there they i.p. injected with DNP. Core body temperature (A, N=13/group) was taken every 10 mins post 
DNP injection for 1 hour and 30 mins for the reminder hour. Mice were euthanized at 2 hours and plasma 
was collected for cytokine analysis (B, N=10/group). Some mice were euthanized at 30 mins for plasma 
histamine analysis (B, N=10/group) Statistical value determined by ANOVA and area under the curve + 
student T test in A. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
A 
B C 
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Figure 20D Histamine Induced Anaphylaxis. Mice were treated with two doses of 
fluoxetine or PBS at 1kg/mg daily. Two hours after the last dose, 5mg of histamine was 
administered, i.p. Core body temperature was measured as in fig. 20A. N=10/group. Statistical 
value determined by area under the curve and student T test . *p<.05; **p<.001; ****p<.0001. 
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Figure 21A Mouse HDM-AHR model 
Mice were sensitized with HDM in Alum intraperitoneally, three days consecutively. Starting on day 11 mice 
were treated daily with fluoxetine or PBS intranasally. On days 13, 16 and 19, were challenged with intranasal 
HDM. Mice were subjected to flexivent on day 23 and sacrificed for data collection.  
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Figure 21B HDM induced lung resistance. Methacholine induced lung resistance was measured in 
anesthetized mice on the Scrieq flexivent instrument. Data is pooled from 2 independent experiments, 
n=8/group. Statistics determined by AUC and one way ANOVA. *p<.0332; **p<.0021;***p<.0002 
****p<.0001 
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Figure 21C Lung Mast Cells. Data is pooled from 2 independent experiments, each experiment with 4 or 5 mice in each 
group. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 21D Lung Eosinophils. Data is pooled from 3 independent experiment with 4-5 mice in each group per 
experiment. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 21E Lung T cells. Data is pooled from 3 independent experiment with 4-5 mice in each group 
per experiment. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 21F BALF Eosinophils. Data is pooled from 3 independent experiment with 4-5 mice in each group. 
Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 21G BALF Neutrophils.  Data is pooled from 2 independent experiment with 4-5 mice in each group. Statistical value 
determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
60 
 
 
Figure 21H BALF Lymphocytes. Data is 
pooled from 2 independent experiment with 
4-5 mice in each group. Statistical value 
determined by ANOVA. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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Figure 21I BALF Cytokines. Data is pooled from 3 or 4 independent experiment with 4-5 mice in 
each group. Statistical value determined by ANOVA. *p<.0332; **p<.0021;***p<.0002 
****p<.0001. 
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Figure 21J Plasma Ig Levels. Data is pooled from 2 independent experiment with 4-5 mice in each 
group per experiment. Statistical value determined by ANOVA and student T test. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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Figure 22 Basophils. Basophils were grown in 20ng/mL IL3 in cRMPI. On day 6 cells were sensitized with IgE. On 
day 7 cells were washed and media was replenished. Cells were plated at 1X106 cells/mL with or without 10uM or 
20 uM fluoxetine. 24 hours later cells were activated with DNP-HSA. Two hours into activation cells were treated 
with 5 uM monensin for 5 hours. Cells were stained for CD49b and P2X7 and fixed in 4% formaldehyde and stored 
in PBS overnight. Cells were then permealized with saponin buffer and stained for intracellular cytokines and P2X3. 
A is from one experiment with 5 populations, each plated in duplicates, two independent repeats showed variable 
suppression of cytokines (independent repeat shown on the next page). B is from two independent experiments 
with 5 or 3 populations analyzed in duplicates, crosslinked and uncrosslinked samples showed no difference and 
are pooled. C is from 3 populations from 1 experiment. Statistical value determined by ANOVA and student T test. 
*p<.0332; **p<.0021;***p<.0002 ****p<.0001 
 
A. 
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Figure 22D Basophils. Basophils were grown in 20ng/mL IL3 in cRMPI. On day 6 cells were sensitized 
with IgE. On day 7 cells were washed and media was replenished. Cells were plated at 1X106 cells/mL 
with or without 10uM or 20 uM fluoxetine. 24 hours later cells were activated with DNP-HSA. Two hours 
into activation cells were treated with 5 uM monensin for 5 hours. Cells were stained for CD49b and 
P2X7 and fixed in 4% formaldehyde and stored in PBS overnight. Cells were then permealized with 
saponin buffer and stained for intracellular cytokines and P2X3. A is from one experiment with 5 
populations, each plated in duplicates, two independent repeats showed variable suppression of 
cytokines (independent repeat shown on previous next page). Statistical value determined by ANOVA 
and student T test. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Figure 23 Eosinophils. Bone marrow derived eosinophils were treated with increasing dosage of fluoxetine for 24 
hours then activated with 300uM ATP for 15 minutes. Cells were stained with zombie aqua dye to indicate live cells, 
surface stained and analyzed by flow cytometry. FLX=fluoxetine. Data is representative of two independent repeats with 
three populations, each in duplicates.  Statistical value determined by ANOVA and student T test. *p<.0332; 
**p<.0021;***p<.0002 ****p<.0001 
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Figure 24 Human Mast cells  HuMC were treated with IgE and fluoxetine at 10µM for 24 hours. Cells were 
washed, fluoxetine was re-added and crosslinked with DNP for 16 hours. Cytokines were measured by ELISA. 
P2X3 staining was measured by FACS. Cytokine data is from two independent experiments. P2X3 staining is a 
combination of 3 donors. Statistical value determined paired student T test. *p<.05; **p<.001; ****p<.0001. 
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Figure 25 P2X3 Expression in male vs. female BMMCs.  BMMCs derived from balb/c male or female mice were 
stained with anti-P2X3 or rabbit IgG isotype control and analyzed by flow cytometry. Data is combined from two 
independent experiments conducted with three populations from each gender, each stained in duplicates. Statistical 
value determined by ANOVA Tukey’s multiple comparisons analysis. *p<.0332; **p<.0021;***p<.0002 ****p<.0001 
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Chapter 4: Discussion 
Fluoxetine is an SSRI, a class of anti-depressants that are widely prescribed. It has been 
found by numerous studies to have fewer side effects compared to other anti-depressants. This 
leads to higher compliance. Its long half-life, 3-4 days for fluoxetine and 7-10 days for the active 
metabolite, norfluoxetine, protects against withdrawal phenomenon. The safety of this drug is 
reviewed in this cited meta-analysis93.  Many studies show that SSRIs have immunosuppressive 
properties, although no work has been done to test their effectiveness in allergic disease. We 
show that fluoxetine can suppress of all phases of IgE-induced mast cell activation, specifically 
release of granules, and the production of eicosanoids and cytokines. Fluoxetine can also 
suppress IgE-independent mast cell activation with ATP. Extracellular ATP has been shown to 
accumulate in the airways of human asthmatics and mouse models of asthma94 and to induce 
mast cell degranulation and cytokine production4,36,37. We show that fluoxetine can block both 
modes of mast cell activation at the signaling levels; fluoxetine suppressed FcRI-mediated 
phosphorylation events and ATP-induced NFB activation.  Further, these effects were 
consistent in vivo using models of anaphylaxis and airway inflammation.  
 We show that fluoxetine effects are not mast cell-restricted, since it also suppressed 
ATP-mediated eosinophil degranulation. Eosinophils are effector cells with potent granular 
mediators that can cause tissue damage if release is uncontrolled, as in allergic inflammation95. 
It is known that inflamed tissues have high extracellular ATP present that can potentiate 
eosinophil activation and recruitment. Eosinophils can be activated by extracellular ATP in the 
asthmatic airways through P2X1 signaling. Interestingly rather than degranulation or cytokine 
production, P2X1 has been shown to mediate eosinophil adhesion96. Another study shows that 
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ATP can induce eosinophil migration into the peritoneal cavity of rats97. Human eosinophils 
were also shown to migrate towards ATP in vitro98. Thus fluoxetine effects on eosinophils has 
clinical relevance.  
 We found that fluoxetine can reduce multiple parameters of HDM-induced airway 
hyperresponsiveness and inflammation. More importantly, it suppressed allergic inflammation 
in sensitized mice, after a B cell response has already begun. Allergic rhinitis and allergic asthma 
affect 15% and 11% of the US population, respectively99 7. Current treatments have limited 
efficacy or high costs (anti-IgE treatment) that limit clinical use or patient access. Leukotriene 
receptor antagonists100 show improvement in lung function in 35-50% of patients. Inhaled 
corticosteroids are considered first line treatment for moderate to severe asthma, however in a 
clinical setting, inhaled corticosteroids and leukotriene receptor antagonists show similar 
effectiveness101. Given the results of this study and fluoxetine’s high capacity to concentrate in 
tissues79,80 where mast cells reside and many allergens are first encountered, fluoxetine may be 
a viable option for allergy therapy, perhaps in combination with other treatments. 
Furthermore, because fluoxetine treatment improved both AHR and inflammation, it may help 
circumvent the issues with current treatment options that show effectiveness in only one or the 
other.  
We reveal that fluoxetine appears to act by antagonizing P2X3 expressed on BMMCs 
and human skin mast cells. Since two different inhibitors of P2X3 significantly suppressed IgE-
mediated mast cell function, this is a logical target for further study both from the perspective 
of understanding its role in mast cell function and for developing new therapeutics. P2X3 
inhibitors are already an interest of pharmacological companies. The P2X3 inhibitor, gefapixant, 
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has been in phase 2 clinical trials for chronic cough. Our study suggests that this drug should be 
tested for treatment of mast cell related disease. Very little is currently known about P2X3 
function on mast cells. Early studies screening mast cells for P2X expression did not identify 
P2X3. There could be many reasons P2X3 was undetected. First, this study used PCR, and 
primers may miss certain isoforms. There are 6 different isoforms of P2X3 currently known. 
Second, this study scanned the LAD2 cell line for expression and only confirmed positive hits 
with primary cells. It is possible that this cell line does not produce P2X3 but primary mast cells 
do. Further, LAD2 cells are of male origin. We have data suggesting that mast cells of male 
background have little to no P2X3 expression compared to female mast cells (Figure 25). All our 
human mast cells are of female origin. This is backed up by several studies finding that P2X3 
expression and function is controlled by estrogen in humans and mice102–104. Interestingly, mice 
lacking estrogen receptor alpha and beta show decreased P2X3 expression on sensory 
neurons105.    
A limitation of our study is that ATP activation is not specific for P2X3, rather all P2X 
receptors on mast cells are responding to this stimulus. Given that mast cells express at least 4 
P2X receptors, and there is no naturally occurring ligand that selectively activates P2X3, we 
cannot exclude contributing stimuli from other P2X receptors without knockouts of each. We 
attempted to minimize activation of P2X7 in our studies by using a relatively low ATP dose of 
150 M or 300 M. P2X7 has a lower affinity for ATP than P2X3, so it requires a much higher 
dose to become activated106. However, our evidence that fluoxetine can suppress this non-
specific stimulus may make it a strong drug candidate, since ATP will likely act on several 
receptors at a given time. Continued studies will utilize P2X3 KO mice, mast cell-specific P2X3 
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KO mice, and mast cell-specific P2X1,4,7 KO mice. There are many unanswered questions. We 
do not know how or why P2X3 inhibition suppresses Syk phosphorylation, which is one of the 
earliest steps in FcRI signaling. We do not know if P2X3 on mast cells has signaling capacities 
outside of calcium influx. We also do not know how P2X3 expression is regulated on mast cells, 
including how fluoxetine reduces its surface levels. 
Another limitation is that we have not assessed the mechanism of suppression in HDM-
induced lung inflammation. It is unlikely that P2X3 suppression alone caused the broad 
suppression of nearly all parameters we measured. It is interesting to note that some studies 
show that blocking ATP in mouse models of asthma with ATPase causes significant suppression 
of AHR and lung inflammation94,107. Some clues from the literature show that fluoxetine can 
suppress Th1 development61. This may also be true for Th2 cells, and our data may support this 
since Th2 numbers in the lungs were lower in the fluoxetine treated mice. However, further 
studies need to be conducted to verify this hypothesis.  
Overall, we show that fluoxetine suppresses IgE- and ATP-mediated mast cell activation. 
We show that potent lipid mediators, cytokines and degranulation are all attenuated by this 
FDA-approved drug. This is true for human mast cells, as well as other innate immune cells and 
is consistent in relevant in vivo models. We show for the first time that human skin mast cells 
express P2X3, and that P2X3 inhibition may be a viable therapeutic target for allergies and mast 
cell related disorders. These data offer a new understanding of how FcRI function may be 
enhanced by rapid ATP secretion that forms a positive feedback loop via P2X3, and suggest that 
suppressing P2X3 may provide clinical benefit to allergic disease. 
 
72 
 
 
 
 
 
 
 
 
 
Figure 26 Summary figure  
We show that fluoxetine treatment attenuates IgE-mediated signaling, calcium influx, degranulation and 
cytokine production. Our data suggests a positive feedback loop via the ATP-P2X3 axis. The findings of 
this study support the hypothesis that fluoxetine blocks this positive feedback loop to diminish IgE 
mediated mast cell activation.  
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